TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04197908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EGBD)
Description: As listed in the arms description
Study: NCT02064153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cool dialysate
Description: Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm dialysate
Description: All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
Study: NCT02337322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/r
Study: NCT01200186

Intervention type: DRUG
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: At the discretion of the attending physician

Intervention type: DRUG
Intervention: Progestin Only Pills
Description: At the discretion of the attending physician
Study: NCT03826030

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose tDCS
Description: The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High dose tDCS
Description: The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mCIMT
Description: All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mCIMT
Description: All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: mCIMT
Description: All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
Study: NCT06693024

Intervention type: DRUG
Intervention: neratinib
Description: neratinib 240mg qd for 1 year
Study: NCT04097860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message including biomarker of breast pumping adequacy
Description: The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
Study: NCT03967522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
Study: NCT06698185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Materna Prep Device
Description: Materna Prep Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham Control
Study: NCT04060784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Description: Failing tooth will be extracted and immediate placed endosseous implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Description: Failing tooth will be extracted and immediate placed endosseous implant
Study: NCT03923673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericardiotomy
Description: The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
Study: NCT01049750

Intervention type: OTHER
Intervention: type 2 diabetic patients
Description: males; type 2 diabetic patients
Study: NCT03749382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AprilAge- facial morphing appearance based intervention for smoking
Description: Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AprilAge- facial morphing appearance based intervention for smoking
Description: Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document.
Study: NCT00081471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: 0.45 micrograms/kg sc (starting dose) weekly
Study: NCT03755154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S65487- initial scheme
Description: S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S65487 - alternative scheme
Description: S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
Study: NCT04588077

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heplisav-B Injectable Product, 2-dose regimen
Description: Investigators will randomly assign patients into a 2-dose regimen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heplisav-B Injectable Product, 2-dose regimen
Description: Investigators will randomly assign patients into a 2-dose regimen.
Study: NCT00081471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 0.6 micrograms/kg sc (starting dose) once every 2 weeks
Study: NCT01241136

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: open wide-excision pilonidal cystectomy
Description: traditional open wide-excisional pilonidal cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive pilonidal cystotomy
Description: unroofing the cyst cavity and curettage the cyst
Study: NCT04588077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heplisav-B Injectable Product, 3-dose regimen
Description: Investigators will randomly assign patients into a 3-dose regimen.
Study: NCT03606135

Intervention type: OTHER
Intervention: The Pneumonia Group

Intervention type: OTHER
Intervention: The Control Group
Study: NCT05299489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct restoration
Description: Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration, bonding, applying composite and assessment of occlusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Indirect restoration
Description: Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. Preparation walls were vertical according to the longitudinal axis of the tooth and the occlusal depth 2 mm. The impressions were taken for both jaws and the bite were recorded for the using red wax. The cavity in example were painted with insulating material. Indirect composite resin were applied, finishined and polished.~Cementation:~Tooth surface: The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration: application of silane coupling agent to enhance the formation of resin tags.~Dual cure resin cement was used for final cementation followed by an assessment of occlusion.
Study: NCT03141801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training
Description: cuff is inflated to 80% of an individuals limb occlusion pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training
Description: cuff is inflated to 80% of an individuals limb occlusion pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercise with BLAST Leg Press System
Description: 4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise with BLAST Leg Press System
Description: 4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concentric Exercise with BLAST Leg Press System
Description: 4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric Exercise with BLAST Leg Press System
Description: 4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
Study: NCT03028025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StatSeal
Description: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR Band
Description: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
Study: NCT02452970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin
Description: RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
Study: NCT01270893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
Study: NCT03753568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic medicine reminder system
Description: Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
Study: NCT03742492

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal containing canned tuna + fish oil (5 g EPA + DHA)
Description: Meal containing canned tuna + fish oil (5 g EPA + DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal containing canned tuna + soybean oil
Description: Meal containing canned tuna + soybean oil
Study: NCT03472482

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: non-invasive retinal imaging
Study: NCT01974674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation of intrahepatic islet
Study: NCT03574467

Intervention type: BEHAVIORAL
Intervention: Bobath Neurodevelopmental Treatment Approach
Description: The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.

Intervention type: BEHAVIORAL
Intervention: Bobath Neurodevelopmental Treatment Approach
Description: The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
Study: NCT00962065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Low Dose
Description: A low dose of LX4211; daily oral intake for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 High Dose
Description: A high dose of LX4211; daily oral intake for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake for 28 days
Study: NCT00772512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: 5 mg capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: 15 mg capsule, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, single dose
Study: NCT01340287

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (1 test product/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (1 control product/day)
Study: NCT01617096

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
Study: NCT04341844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
Study: NCT04497246

Intervention type: OTHER
Intervention: Questionnaire
Description: Data collection by means of various questionnaires

Intervention type: OTHER
Intervention: Questionnaire
Description: Data collection by means of various questionnaires
Study: NCT00624130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin 20
Description: Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercilon
Description: Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Study: NCT01745627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alex laser
Study: NCT01847638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolensa (bromfenac 0.07%)
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilevro (nepafenac 0.3%)
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
Study: NCT04185324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard zippering vest
Description: Standard zippering vest used to teach zippering

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified zippering vest
Description: Modified zippering vest used to teach zippering, along with related story
Study: NCT02154269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with G-CSF (Granulocyte colony stimulating factor)
Description: Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
Study: NCT01937208

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiation therapy in both arms

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiation therapy in both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with radiation
Description: docetaxel plus cisplatin were used weekly in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemotherapy with radiation
Description: docetaxel plus cisplatin were used weekly in both arms
Study: NCT02190435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ADAPT computer-assisted navigation
Description: Adaptive Positioning Technology for Gamma 3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Conventional Technique
Study: NCT02083445

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cognitive activities
Description: Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle electro-stimulation
Description: A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hypobaric hypoxia
Study: NCT03408080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-4157
Description: BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
Study: NCT01429012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Culture medium without MSC.
Description: 2 ml of culture medium.
Study: NCT03943511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antibiotics-Close Monitoring
Description: To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
Study: NCT04250415

Intervention type: PROCEDURE
Intervention: Surgery
Study: NCT03566667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Betablocker